መነሻ › ኖን-ስማል ሴል የሳንባ ካንሰር › ኒብራስካ › Grand Island
በGrand Island፣ NE ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ ክሊኒካዊ ጥናቶች
ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ 5 ጥናቶች በGrand Island እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።
Official study text (English)
ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Nebraska Cancer Specialists, Grand Island
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island, Grand Island
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional, Grand Island
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Research Site, Grand Island
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
- Local Institution - 007-590D, Grand Island
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Nebraska Cancer Specialist, Grand Island
በሌሎች ከተሞች ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ ጥናቶች
- Houston, TX145 ጥናቶች
- New York City, NY121 ጥናቶች
- Arlington, VA104 ጥናቶች
- Nashville, TN97 ጥናቶች
- Boston, MA90 ጥናቶች
- Los Angeles, CA87 ጥናቶች
- St. Louis, MO73 ጥናቶች
- Chicago, IL61 ጥናቶች
- Baltimore, MD60 ጥናቶች
- San Antonio, TX59 ጥናቶች
- Columbus, OH57 ጥናቶች
- Washington, DC55 ጥናቶች
በGrand Island ውስጥ ያሉ ሌሎች ጥናቶች
ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።